Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
Go back to Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 43.45 +0.38 (0.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $43.07 | 52 Week High | $59.00 | |||
| Open | $43.66 | 52 Week Low | $32.80 | |||
| Day High | $43.71 | P/E | N/A | |||
| Day Low | $43.07 | EPS | $0.00 | |||
| Volume | 4,483,932 | |||||
